SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Tadashi Namisaki, Ryuichi Noguchi, Kei Moriya, Mitsuteru Kitade, Yosuke Aihara, Akitoshi Douhara, Norihisa Nishimura, Kosuke Takeda, Yasushi Okura, Hideto Kawaratani, Hiroaki Takaya, Kenichiro Seki, Hitoshi Yoshiji, Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis, Journal of Gastroenterology, 2015,

    CrossRef

  2. 2
    Samar A. Asker, Shireen A. Mazroa, Vivian Boshra, Ahmed M. Hassan, Biochemical and histological impact of direct renin inhibition by aliskiren on myofibroblasts activation and differentiation in bleomycin induced pulmonary fibrosis in adult mice, Tissue and Cell, 2015,

    CrossRef

  3. 3
    Yuka Hayashizaki-Someya, Eiji Kurosaki, Toshiyuki Takasu, Hikaru Mitori, Shunji Yamazaki, Kumi Koide, Shoji Takakura, Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats, European Journal of Pharmacology, 2015, 754, 19

    CrossRef

  4. 4
    Sahar Kamal, Aliskiren Augments the Activities of Anti-Oxidant Enzymes in Liver Homogenates of DOCA Salt-Induced Hypertensive Rats, Advances in Enzyme Research, 2014, 02, 02, 92

    CrossRef

  5. 5
    Manabu Kishina, Masahiko Koda, Jun Kato, Shiho Tokunaga, Tomomitsu Matono, Takaaki Sugihara, Masaru Ueki, Yoshikazu Murawaki, Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice, Hepatology Research, 2014, 44, 8
  6. 6
    Masafumi Ono, Third-generation inhibitor for the renin–angiotensin system: Can it strongly protect against progression of hepatic fibrosis in non-alcoholic steatohepatitis?, Hepatology Research, 2013, 43, 11